After Hours Market: Marinus Pharma, Novus Therapeutics And NextEra Energy Gain; Nikola Slips

Marinus Pharmaceuticals, Inc. (MRNS) - Shares of the drug company surged nearly 70% in after-hours trading on Monday. Marinus announced that its Ganaxolone achieved primary endpoint in late stage trial for CDKL5 deficiency disorder, a rare form of genetic epilepsy. The company plans to submit New Drug Application by mid-2021 with commercial launch targeted for first half of 2022.

Novus Therapeutics, Inc. (NVUS) - The nano-cap company's stock soared over 140% in after-hours period after the company announced it has completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.

NextEra Energy, Inc. (NEE) - Shares of the company jumped nearly 6% after the bell on Monday after the company lifted its financial outlook and announced a 4:1 stock split. For 2021, NextEra Energy increased its financial expectations by $0.20 and now expects adjusted earnings of $9.60 to $10.15 per share. Analysts polled by Thomson Reuters currently estimate earnings of $9.88 per share. For 2022 and 2023, NextEra Energy expects to grow 6% to 8%

Nikola Corp. (NKLA) - The electric car company's shares slipped 8% in extended trading on Monday after a Bloomberg report that the Securities and Exchange Commission will examine the company after a short seller report alleged that Nikola deceived investors about its business prospects. Nikola said that the report had "dozens" of inaccuracies and that it had contacted the SEC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT